- Company
- Outpatient Rx amount for major chronic diseases decreased
- by Chon, Seung-Hyun Jun 22, 2020 06:08am
- Prescriptions for chronic diseases such as hyperlipidemia, hypertension, and diabetes, which have the largest sales due to COVID-19, have been reduced by half. According to UBIST, a drug research agency on the 17th, the outpatient prescription size was &8361;2,360 billion in April and May, a 9.0% decrease from the same period last year. In A
- Company
- “Immunotherapy Tecentriq, a crucial turning point for TNBC"
- by Eo, Yun-Ho Jun 19, 2020 06:20am
- “The release of immunotherapy makes a significant difference in treating triple-negative breast cancer with limited treatment options.” To this date, treating the triple-negative breast cancer (TNBC), reacting negatively on all receptors (estrogen, progesterone and HER2), has not been struggling with high unmet medical need. Progra
- Company
- KRPIA-KPBMA welcome MOHW revising stepped pricing reduction
- by Eo, Yun-Ho Jun 18, 2020 06:28am
- “We sincerely welcome the Ministry of Health and Welfare’s reasonable decision.” The pharmaceutical industry, especially the companies preparing an ownership change in drug item, seemed to be relieved with the latest decision by the Korean government. On June 17, Ministry of Health and Welfare (MOHW) preannounced the revised Standa
- Company
- It will be Fulcare & Dermatix to communicate more
- by Eo, Yun-Ho Jun 17, 2020 06:21am
- 'Consumer Healthcare' now represents the OTC business. In the pharmacy market, the management relying on the profits of pharmaceuticals is limiting, and the interest in improving profits through OTC sales is increasing. In this situation, multinational pharmaceutical companies are attracting attention as long as they are promoting the st
- Company
- Roche’s Tecentriq is preparing to enter the Korean market
- by Eo, Yun-Ho Jun 17, 2020 06:21am
- Immune anticancer drugs are expected in the first line of hepatocellular carcinoma in Korea. According to the related industry, Roche Korea has recently expanded its indications for the combination therapy of Tecentriq (Atezolizumab) in combination with Avastin (Bevacizumab) for the treatment of patients with unresectable or metastatic hep
- Company
- Hanmi Science commenced development of oral COVID-19 vaccine
- by Jun 17, 2020 06:21am
- Hanmi Science, a holding company of Hanmi Pharm Group, is developing 'COVID-19 vaccine for oral use'. In addition, a research center of &8361;300 billion is established in Pohang, and an unprecedented personnel system, such as a 100% increase in salary for outstanding talent, is introduced. Hanmi Science unveiled 'The Six Visions for the Pos
- Company
- Takeda's partners relieved their worries
- by An, Kyung-Jin Jun 17, 2020 06:20am
- Domestic partner companies are nervous as Takeda officially sells its business units. As Celltrion decided to maintain a co-sales contract for 18 items that take over copyrights, immediate changes were avoided, but it may be difficult to maintain copyrights after changing partners. According to the industry on the 15th, Celltrion is expec
- Company
- Korean drug trade in May makes first surplus amid COVID-19
- by Kim, Jin-Gu Jun 16, 2020 06:20am
- In May, the Korean pharmaceutical export volume has hit the historic high. It also was the first month to make pharmaceutical trade surplus in Korea. Europe, where the COVID-19 started spreading later than in Korea, had a sharp surge of demand on essential drug that boosted the drug trade in Korea. ◆New historic high trade volume in t
- Company
- Antidiabetic Suganon readies clinical trial for CAVD
- by Nho, Byung Chul Jun 16, 2020 06:20am
- Diabetes treatment Suganon (evogliptin) has started a clinical trial to receive an indication to treat calcific aortic valve disease (CAVD). In North America, the number of CAVD patients is projected at 1.50 million to 11.5 million (prevalence rate ranging from 2.5 percent to 25 percent in age group over 65), and the related prosthetic
- Company
- Takeda to sell 18 items of diabetes & OTC to Celltrion
- by Eo, Yun-Ho Jun 16, 2020 06:19am
- The sale of some items of diabetes and OTC by Takeda was confirmed. Celltrion is the company that acquires these items. Recently, the headquarters of Takeda trademarks, for patents, trademarks, and rights to sell 18 non-core generic and OTC sold in nine countries, including Korea, Thailand, Taiwan, Hong Kong, Macau, Philippines, Singapore,
